Pilar
Pilar
Pilar, Argentina18 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH | Digestive System Diseases, Fibrosis, Nutritional and Metabolic Diseases, Pathologic Processes, Pathological Conditions, Signs and Symptoms, fatty liver disease, liver disorder, metabolic disease, metabolic dysfunction-associated steatotic liver disease | Recruiting | Phase 3 | 2026-10-05 | NCT06419374 | |
| A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis) | Digestive System Diseases, Fibrosis, Nutritional and Metabolic Diseases, Pathologic Processes, Pathological Conditions, Signs and Symptoms, fatty liver disease, liver disorder, metabolic disease, metabolic dysfunction-associated steatotic liver disease | Recruiting | Phase 3 | 2026-10-05 | NCT06318169 | |
| FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC | Bone Diseases, Developmental, Camurati-Engelmann disease, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Head and Neck Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, bone disorder, carcinoma, epithelial neoplasm, head and neck squamous cell carcinoma, hereditary disease, laryngeal disorder, musculoskeletal system disorder, neoplasm, osteochondrodysplasia, otorhinolaryngologic disease, respiratory system disorder, squamous cell carcinoma | Recruiting | Phase 2 / Phase 3 | 2026-10-02 | NCT06788990 | |
| A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heart | cardiovascular disorder, heart disorder, heart failure | Recruiting | Phase 3 | 2026-10-01 | NCT06935370 | |
| LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis | Metabolic Dysfunction Associated Steatohepatitis | Recruiting | Phase 3 | 2026-10-01 | NCT06632457 | |
| LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis | Digestive System Diseases, Fibrosis, Fibrosis, Liver, Pathologic Processes, Pathological Conditions, Signs and Symptoms, cirrhosis of liver, liver disorder | Recruiting | Phase 3 | 2026-10-01 | NCT06632444 | |
| A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart Failure | cardiovascular disorder, heart disorder, heart failure | Recruiting | Phase 3 | 2026-10-01 | NCT06424288 | |
| A Long-Term Study of Elafibranor in Adult Participants With Primary Biliary Cholangitis | Digestive System Diseases, Fibrosis, Pathologic Processes, Pathological Conditions, Signs and Symptoms, bile duct disorder, biliary tract disorder, cholestasis, cirrhosis of liver, intrahepatic cholestasis, liver disorder, primary biliary cholangitis | Recruiting | Phase 3 | 2026-10-01 | NCT06016842 | |
| A Study to Find Out if BI 764198 Helps Adults and Adolescents With a Kidney Condition Called Focal Segmental Glomerulosclerosis (FSGS) | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Urogenital Diseases, focal segmental glomerulosclerosis, glomerulonephritis, kidney disorder, nephritis, urinary system disorder | Recruiting | Phase 3 | 2026-09-30 | NCT07220083 | |
| A Study to Test if Tenecteplase Helps People to Recover From an Acute Stroke When Given More Than 4.5 Hours After the Person Was Last Seen Well | Acute Ischemic Stroke, brain disorder, cardiovascular disorder, central nervous system disorder, cerebrovascular disorder, ischemic stroke, nervous system disorder, stroke disorder, vascular disorder | Recruiting | Phase 3 | 2026-09-29 | NCT07361302 | |
| Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma | Clear-cell metastatic renal cell carcinoma, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, benign urinary system neoplasm, kidney cancer, kidney disorder, neoplasm, urinary system disorder | Recruiting | Phase 3 | 2026-09-29 | NCT07011719 | |
| A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm | Recruiting | Phase 3 | 2026-09-25 | NCT06868277 | |
| A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Squamous NSCLC | Non-squamous Non-small Cell Lung Cancer | Recruiting | Phase 3 | 2026-09-23 | NCT06627647 | |
| Long-Term, Open-label Study of Oral Deucrictibant Extended-Release Tablet for Prophylaxis Against Angioedema Attacks in Adolescents and Adults With HAE | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Hereditary Complement Deficiency Diseases, Hypersensitivity, Immediate, Primary Immunodeficiency Diseases, Skin and Connective Tissue Diseases, angioedema, cardiovascular disorder, hereditary angioedema, hereditary disease, immune system disorder, inborn error of immunity, skin disorder, skin vascular disease, urticaria, vascular disorder | Enrolling by invitation | Phase 3 | 2026-09-22 | NCT06679881 | |
| A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm | Recruiting | Phase 3 | 2026-09-18 | NCT06692738 | |
| Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm | Recruiting | Phase 3 | 2026-09-15 | NCT06899126 | |
| STOP-HAE: A Phase 3 Study of ADX-324 in HAE | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Hereditary Complement Deficiency Diseases, Hypersensitivity, Immediate, Primary Immunodeficiency Diseases, Skin and Connective Tissue Diseases, angioedema, cardiovascular disorder, hereditary angioedema, hereditary disease, immune system disorder, inborn error of immunity, skin disorder, skin vascular disease, urticaria, vascular disorder | Recruiting | Phase 3 | 2026-09-10 | NCT06960213 | |
| A Study of Baricitinib (LY3009104) in Children From 6 Years to Less Than 18 Years of Age With Alopecia Areata | Pathological Conditions, Anatomical, Pathological Conditions, Signs and Symptoms, Skin and Connective Tissue Diseases, alopecia, disorder of pilosebaceous unit, hypotrichosis, skin disorder | Recruiting | Phase 3 | 2026-09-08 | NCT05723198 |